Cardiome strikes US$86-million deal with Fujisawa

Guest Contributor
October 27, 2003

Cardiome Pharma Corp has entered into a US$68-million strategic partnership agreement with Fujisawa Healthcare Inc, the US subsidiary of Fujisawa Pharmaceutical Co Ltd of Japan. The deal pivots on co-development of RSD1235, Cardiome’s intravenous antiarrhythmic agent. Fujisawa will pay Cardiome $10 million up front, $54 million in milestone payments and $4 million in an equity placement with Fujisawa Healthcare. Fujisawa gains exclusive commercialization rights to RSD1235 to treat atrial fibrillation and atrial flutter. It will cover 75% of future clinical development costs while Cardiome will cover 25%....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.